



## **Pluristem CEO Zami Aberman to Present at Phacilitate Cell & Gene Therapy Forum 2014**

*Aberman to share Pluristem's expertise in cell therapies at four sessions during the three day conference*

HAIFA, ISRAEL, January 27, 2014- Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell product candidates, today announced the Company's Chairman and CEO, Zami Aberman, will make two presentations and speak in panel discussions at the 10th Annual Phacilitate Cell & Gene Therapy Forum. The conference will take place on January 27<sup>th</sup> through 29<sup>th</sup>, 2014 in Washington D.C.

"We look forward to contributing to this year's Phacilitate Cell & Gene Therapy Forum by presenting our successful strategies in cell therapy development, manufacturing and clinical trials. This gathering, which includes the leaders in cell therapy science, investors, and regulators, is important to advancing the entire cell therapy industry to deliver much needed healthcare solutions," Mr. Aberman stated.

Mr. Aberman will be a panel member on the following sessions:

- Date: Jan 28<sup>th</sup>, 2014, 10:15AM ET  
Panel Discussion  
Topic: *How are phase I/II C&GT companies "blocking and tackling" to prepare for commercialization? What are the key questions to ask your development and commercial teams before you reach phase III?*
- Date: Jan 28<sup>th</sup>, 2014, 05:20PM ET  
Panel Discussion  
Topic: *What are the key issues for consideration to assess the viability of such a business model?*

Mr. Aberman will be the presenter for the following sessions:

- Date: Jan 29<sup>th</sup>, 2014, 10:55AM ET  
Topic: *3D culturing of MSC opens new possibilities for screening, toxicology and diagnostics*
- Date: Jan 29<sup>th</sup>, 2014, 12:45PM ET

Focus Session 3

Case Study: *The challenges in the design and implementation of a multi-national, FDA/EMA approved PAD clinical study*

### **About Pluristem Therapeutics**

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit [www.pluristem.com](http://www.pluristem.com), the content of which is not part of this press release.

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

#### **Contact:**

Pluristem Therapeutics Inc.:

Karine Kleinhaus, MD, MPH

Director of Investor Relations  
1-914-512-4109  
[karinek@pluristem.com](mailto:karinek@pluristem.com)

Daya Lettvin  
Investor & Media Relations Director  
+972-54-674-5580  
[daya@pluristem.com](mailto:daya@pluristem.com)